PetSmart® Launches the MicrocynAH® Family of Pet Healthcare Products for Dogs, Cats, Birds, Reptiles and Small Animals
28 February 2017 - 8:05PM
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today
announced that PetSmart, Inc., the leading pet specialty retailer
in North America, has launched the company’s MicrocynAH® family of
animal healthcare products this month with complete chain-wide
availability of the products in 1,500-plus PetSmart stores across
North America.
“We are excited to offer this comprehensive family of one-step
wound, skin, eye and ear care pet products to our health and
wellness-conscious pet parents,” said Sherry Jane Love, VP of hard
goods merchandising, PetSmart, the buying area for problem-solution
pet products. “These products join our strong Problem-Solution
offerings and bring forward new ways pet parents can tackle various
challenges they may face with their pets.”
MicrocynAH products available this spring at all PetSmart stores
include: Wound & Skin Care Spray, Wound & Skin Care
Hydrogel, Ophthalmic Gel, Eye & Ear Wash, Anti-Itch Gel Spray
with Dimethicone and Hot Spot Gel Spray with Dimethicone. The
products are well suited for dogs, cats, birds, reptiles and other
small animals and are based upon the clinically proven Micrcocyn®
Technology with 53 patents, 30-plus clinical studies and 15 FDA
clearances. This line of products has successfully treated over ten
million patients worldwide.
“We are eager to provide PetSmart pet parents with the latest
advance in animal healthcare,” said Dan McFadden, Sonoma VP of
animal wellness. “All these products were originally created
for human healthcare—and once demonstrated to be both safe and
highly efficacious in that two-legged realm—were refined and
customized for use with companion animals. With superior
shelf stability and no-sting, safe-as-saline formulations, pet
parents will be amazed with the fast-acting performance of
MicrocynAH.”
About PetSmart® PetSmart, Inc. is the largest
specialty pet retailer of services and solutions for the lifetime
needs of pets. At PetSmart, we love pets, and we believe pets make
us better people. Every day with every connection, PetSmart’s
passionate associates help bring pet parents closer to their pets
so they can live more fulfilled lives. This vision impacts
everything we do for our customers, the way we support our
associates and how we give back to our communities. We employ
approximately 55,000 associates, operate approximately 1,500 pet
stores in the United States, Canada and Puerto Rico and 204
in-store PetSmart® PetsHotel® dog and cat boarding facilities.
PetSmart provides a broad range of competitively priced pet food
and pet products and offers dog training, pet grooming, pet
boarding, PetSmart Doggie Day Camp day care services and pet
adoption services in-store. Our portfolio of digital resources for
pet parents – including PetSmart.com, PetFoodDirect.com, Pet360.com
and petMD.com – offers the most comprehensive online pet supplies
and pet care information in the U.S. Through our in-store pet
adoption partnership with independent nonprofit organizations,
PetSmart Charities® and PetSmart Charities™ of Canada, PetSmart
helps to save the lives of more than 500,000 homeless pets each
year. In Sept. of 2016, PetSmart announced that it had hit a major
milestone: 7 million pets adopted through its in-store adoption
program since starting this effort in the late 1980s.
About Sonoma Pharmaceuticals, Inc.Sonoma
Pharmaceuticals (formerly Oculus Innovative Sciences) is a
specialty pharmaceutical company that develops and
markets solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “will pay,”
“expected” and “delivered,” among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be
able to penetrate one or more targeted markets, revenues will
not be sufficient to fund further development and clinical studies,
the Company may not meet its future capital needs, the Company
may not be able to obtain additional funding, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K for
the fiscal year ended March 31, 2016. The Company disclaims
any obligation to update these forward-looking statements, except
as required by law.
Sonoma Pharmaceuticals® and Microcyn® Technology are trademarks
or registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024